Search
-
Short-Form Social Misfits
The next creative shift that will drive advertising effects in TikTok, Instagram Reels and YouTube Shorts
-
Ipsos Synthesio unveils Signals GenAI, providing instant consumer insights
Signals GenAI, our pioneering Generative AI platform app, empowers you to transform real-time consumer signals into actionable insights within 60 seconds. Now everyone can turn millions of consumer voices into actionable insights with just three simple clicks!
-
From unstructured data to intelligence
Our new Ipsos Views paper from Ipsos’ Social Intelligence Analytics team examines the journey of social media data, from tech platforms to research solutions.
-
Artificial intelligence: Four points of vigilance
This article on AI from Helen Zeitoun, CEO Science Organisation and CEO Ipsos in France, was originally published in French in Strategies, March 2019.
-
Virtual Reality: Hype or the Future?
Virtual Reality (VR) technology has been around for at least a decade and you could say it’s clearly gone from sci-fi to sci-fact. However, it’s still seen as a new technology and has not hit mass adoption; so what has gone wrong?
-
Four Ways Agile Research Will Evolve to Drive Innovation
In today’s fast-moving, shape-shifting world, it seems virtually every business, every marketer, and every researcher wants to be agile. But, what exactly does agility mean?
-
Smartificial Intelligence
Artificial Intelligence is often mooted as the ‘future’ for our industry. Many lead us to believe that we are headed for an AI utopia; that ‘optimised’ ad experiences fuelled by big data insights gleaned solely by machines, tailored to individuals, and served to them programatically with impeccable timing in the right time and right context, is almost within reach. However, when we take a step back to consider this, how close are we really; and is it even what we want at all?
-
Conquering Complexity: The Coming Revolution in Oncology Biomarker Testing
Despite the advent of targeted therapies and the associated rise in the use of companion and complementary diagnostics, we are only just emerging from the initial exploratory stages of oncology biomarker testing. As will be argued in this paper, we are on the cusp of a much more radical revolution, and the molecular diagnostics landscape is set to change dramatically in the coming decades. It is crucial that any company entering this space prepare for this imminent upheaval and plan their launch strategy accordingly.